Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
320 participants
INTERVENTIONAL
2012-09-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Provoked Craving Relief Study by NRT
NCT01476202
Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving
NCT01466361
Provoked Craving Assessment
NCT01506908
Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge
NCT01075659
Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Therapy and Nicotine Gum
NCT01368016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotine Mouth Film
mint nicotine mouth film, buccal administration
Nicotine
Comparison of different dosage forms of nicotine
Nicotine Lozenge
nicotine lozenge, buccal administration
Nicotine
Comparison of different dosage forms of nicotine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotine
Comparison of different dosage forms of nicotine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current cigarette smokers who have smoked regularly daily for at least a year,
* Participants who smoke their first cigarette more than 30 minutes after waking up
Exclusion Criteria
* Any participant whose CO level rises during the sequestration period (i.e., the subject's two expired CO assessments immediately prior to the provoked craving paradigm are higher than the mean baseline CO assessment) and, in the opinion of the investigator, may have smoked during that time.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles Clinical Trials
Burbank, California, United States
Central Kentucky Research Associates, Inc.
Lexington, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RH01589
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.